Rafferty Asset Management
MTNB icon

Rafferty Asset Management’s Matinas BioPharma MTNB Stock Holding History

Rafferty Asset Management’s Portfolio MTNB Stock Details MTNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-257
Closed -$10K – 1194
2022
Q1 		$10K Sell
257
-431
-63% -$15.9K ﹤0.01% 1217
2021
Q4 		$35K Buy
+688
New +$36.8K ﹤0.01% 1294

Other funds holding MTNB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return
NRS
Neville Rodie & Shaw New York $1.55B AUM 46.95% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return

Rafferty Asset Management's MTNB Position: Q2 2022 in Review

Rafferty Asset Management sold out of Matinas BioPharma (MTNB) in Q2 2022, closing a stake of 257 shares — an estimated $10K sold.

Rafferty Asset Management first reported a position in MTNB in Q4 2021 and held it in 2 quarters. The position peaked at $35K in Q4 2021. 50 funds tracked by Wall St. Rank hold MTNB as of Q2 2022.

  • Rafferty Asset Management reported no remaining Matinas BioPharma position as of Q2 2022 after selling out during the quarter.
  • Rafferty Asset Management sold 257 Matinas BioPharma shares in Q2 2022, an estimated $10K.
  • Rafferty Asset Management first reported a position in Matinas BioPharma in Q4 2021 and held it in 2 quarters.
  • Rafferty Asset Management's Matinas BioPharma position peaked at $35K in Q4 2021.
  • 50 funds tracked by Wall St. Rank held Matinas BioPharma as of Q2 2022.

Based on Rafferty Asset Management's 13F filing for Q2 2022, filed 12 Aug 2022.